Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Hospitals with higher surgical volumes less likely to cause unintentional serious injuries

Are you scheduled for heart bypass surgery or weight loss surgery? You might want to find out just how frequently different hospitals in your area are performing those procedures before deciding where to go. A new study finds that hospitals with higher surgical volumes for certain procedures are less likely to cause unintentional serious injuries to hospitalized patients when compared to those hospitals that perform the procedures less often.

2 Sep 2011

Waters recognizes Head of TGen's Center for Proteomics for research excellence

Waters Corporation today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation.

26 Aug 2011

Zinc may act as tumor suppressor in commonist form of pancreatic cancer

The essential element zinc has been shown in a new study to be a likely tumor suppressor in the commonist form of pancreatic cancer, University of Maryland scientists report in the current issue of the journal Cancer Biology & Therapy.

26 Aug 2011

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

A $30 million gift from the Commonwealth Foundation for Cancer Research has enabled the Johns Hopkins Kimmel Cancer Center to establish a Center for Personalized Cancer Medicine. The gift from the Richmond, VA- based foundation, will be used to support research and the development of new technologies that pinpoint the novel genetic characteristics of each patient's cancer.

22 Aug 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

W.M. Keck Foundation awards Jefferson scientists with $1M medical research grant

Scientists at Thomas Jefferson University have been awarded a $1 million medical research grant from the W.M. Keck Foundation for an ambitious project looking at the little explored 98 percent of the human genome and what role it may play in the onset and progression of diseases.

4 Aug 2011

UTHealth student receives UNCF/Merck fellowship for multidrug-resistant CDI research

Charles Darkoh, a graduate student at The University of Texas Health Science Center at Houston (UTHealth), has been awarded a fellowship from the United Negro College Fund (UNCF) and Merck for his research into a major health problem - multidrug-resistant Clostridium difficile bacterial infection.

3 Aug 2011

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the treatment of pancreatic cancer.

2 Aug 2011

One in four British women at risk of cancer

A cancer charity revealed figures that show that British women are nearly a fifth more likely to develop cancer at some point during their lives than their European counterparts. Most of it is blamed on lifestyle factors such as obesity and alcohol consumption.

31 Jul 2011

Houston-based Mattress Firm commits to support pancreatic cancer research

Mattress Firm, a leading specialty mattress retailer with more than 720 stores nationwide, is committed to supporting the fight against pancreatic cancer by raising funds for clinical trials through the Translational Genomics Research Institute (TGen) globalCure initiative.

29 Jul 2011

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris Group today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

Tumor marker, endoscopic ultrasound more likely to detect stage 1 pancreatic cancer

Researchers from New England report in a new study that using a tumor marker, serum CA 19-9, combined with an endoscopic ultrasound if the tumor marker is elevated, is more likely to detect stage 1 pancreatic cancer in a high-risk population than by using the standard means of detection.

26 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

SG Austria acquisition benefits Nuvilex with $1.5M in grant funding

Nuvilex, Inc. announced today that as part of its acquisition of SG Austria, Nuvilex will benefit from grant funding previously awarded to SG Austria for its live-cell encapsulation activities and other projects. The total grant funding awarded to SG Austria is approximately $1.5 million.

22 Jul 2011

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

Repligen Corporation today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Gene-based test for distinguishing harmless from precancerous pancreatic cysts

Johns Hopkins scientists have developed a gene-based test to distinguish harmless from precancerous pancreatic cysts. The test may eventually help some patients avoid needless surgery to remove the harmless variety.

21 Jul 2011

Pancreatic Cancer News and Research

Further Reading

Hospitals with higher surgical volumes less likely to cause unintentional serious injuries

Waters recognizes Head of TGen's Center for Proteomics for research excellence

Zinc may act as tumor suppressor in commonist form of pancreatic cancer

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

W.M. Keck Foundation awards Jefferson scientists with $1M medical research grant

UTHealth student receives UNCF/Merck fellowship for multidrug-resistant CDI research

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

One in four British women at risk of cancer

Houston-based Mattress Firm commits to support pancreatic cancer research

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Celgene reports second quarter total revenue of $1.18 billion

Repligen first quarter total revenue increases 9% to $7,654,000

Tumor marker, endoscopic ultrasound more likely to detect stage 1 pancreatic cancer

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

SG Austria acquisition benefits Nuvilex with $1.5M in grant funding

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

Quest receives U.S. patent allowance for cancer combination therapy

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

Gene-based test for distinguishing harmless from precancerous pancreatic cysts

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News